{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:19:03Z","timestamp":1787692743338,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020780","name":"Lucile Packard Foundation for Children's Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","award":["WI234775"],"award-info":[{"award-number":["WI234775"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100276","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:25:34Z","timestamp":1784996734000},"page":"100276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Palbociclib in combination with dexamethasone, bortezomib, and doxorubicin for pediatric relapsed acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2450-8612","authenticated-orcid":false,"given":"Sushmitha Grama","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Kamens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6036-3127","authenticated-orcid":false,"given":"Lianna J.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay M. S.","family":"Balagtas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Rubnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1072-7257","authenticated-orcid":false,"given":"Tanja A.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bneo.2026.100276_bib1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a therapeutic advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100276_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100276_bib3","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bneo.2026.100276_bib4","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.bneo.2026.100276_bib5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1101\/gad.1673908","article-title":"Failure of CDKN2A\/B (INK4A\/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL","volume":"22","author":"Mullighan","year":"2008","journal-title":"Genes Dev"},{"issue":"5","key":"10.1016\/j.bneo.2026.100276_bib6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2012-03-415984","article-title":"Prolonged early G(1) arrest by selective CDK4\/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100276_bib7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia & lymphoma (TACL) study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2026.100276_bib8","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3324\/haematol.2021.279410","article-title":"Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia","volume":"107","author":"Bride","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2026.100276_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/1535-7163.MCT-14-1065","article-title":"Specific antileukemic activity of PD0332991, a CDK4\/6 inhibitor, against Philadelphia chromosome-positive lymphoid leukemia","volume":"15","author":"Nemoto","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.bneo.2026.100276_bib10","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4161\/cc.27757","article-title":"MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL","volume":"13","author":"Van der Linden","year":"2014","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.bneo.2026.100276_bib11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/leu.2015.353","article-title":"CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia","volume":"30","author":"Jena","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2026.100276_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.leu.2402733","article-title":"Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia","volume":"17","author":"Tissing","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2026.100276_bib13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0026-895X(25)09073-X","article-title":"Cell cycle-dependent cytotoxicity, G2\/M phase arrest, and disruption of p34cdc2\/cyclin B1 activity induced by doxorubicin in synchronized P388 cells","volume":"49","author":"Ling","year":"1996","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100276_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28879","article-title":"A phase I trial of the CDK 4\/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: a Pediatric Brain Tumor Consortium study (PBTC-042)","volume":"68","author":"Van Mater","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.bneo.2026.100276_bib15","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/pbc.22414","article-title":"Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference","volume":"54","author":"Horton","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2026.100276_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2014-02-558114","article-title":"Requirement for CDK6 in MLL-rearranged acute myeloid leukemia","volume":"124","author":"Placke","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2026.100276_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30609","article-title":"Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: a Children's Oncology Group study (AINV18P1)","volume":"70","author":"Raetz","year":"2023","journal-title":"Pediatr Blood Cancer"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:29:58Z","timestamp":1787689798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026000877"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100276","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palbociclib in combination with dexamethasone, bortezomib, and doxorubicin for pediatric relapsed acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100276"}}